General Hospital Psychiatry
Volume 30, Issue 1 , Pages 26-31, January 2008

Trajectories of improvement for six depression-related outcomes

  • James E. Aikens, Ph.D.

      Affiliations

    • Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109-5708, USA
    • Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109-5708, USA
    • Corresponding Author InformationCorresponding author. Department of Family Medicine; University of Michigan, Ann Arbor, MI 48109-5708, USA. Tel.: +1 734 998 7120x320; fax: +1 734 998 7335.
  • ,
  • Kurt Kroenke, M.D.

      Affiliations

    • Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-3002, USA
    • Regenstrief Institute, Indianapolis, IN 46202-3012, USA
  • ,
  • Donald E. Nease Jr., M.D.

      Affiliations

    • Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109-5708, USA
  • ,
  • Michael S. Klinkman, M.D., M.S.

      Affiliations

    • Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109-5708, USA
    • Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109-5708, USA
  • ,
  • Ananda Sen, Ph.D.

      Affiliations

    • Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109-5708, USA
    • Department of Statistics, and Center for Statistical Consultation and Research (CSCAR), University of Michigan, Ann Arbor, MI 48109-1070, USA

Received 10 August 2007; accepted 11 October 2007.

Abstract 

Objective

Although depression treatment improves diverse outcomes, it is unclear whether these improvements are comparable in magnitude and timing. The objective was therefore to compare treatment-related improvements in depressive symptoms, work and social functioning, hopefulness, somatic complaints and positive well-being.

Method

Secondary analysis of a large clinical trial of selective serotonin reuptake inhibitors for primary care depression. Depressed patients (n=573) from 37 practices from two primary care networks were randomized to fluoxetine, paroxetine or sertraline, and then followed naturalistically. At 1, 3, 6 and 9 months after treatment initiation, assessments were made of depressive symptom severity, social and work functioning, positive well-being, hopefulness beliefs and somatic complaints. Data were analyzed with linear regression modeling.

Results

Although 68% and 88% of total mood improvement occurred by Months 1 and 3, respectively, improvement plateaued sooner for somatic complaints (P=.001 at Month 1), and more gradually for hopefulness [P (Month 1)=.015, P (Month 3)=.036]. Although magnitude of improvement was interrelated across outcomes, timing of mood improvement was unrelated to the timing of improvement in both somatic complaints and hopefulness. Improvement in somatic complaints was primarily attributable to improvements in head, back and stomach pain.

Conclusions

Work and social functioning, and positive affect improve synchronously with mood. Compared to mood, improvement in pain complaints peaks earlier, whereas improvement in hopefulness is much more linear over time. Because depression treatment response appears to be complex and multidimensional, a broader conceptualization of depression remission may be indicated.

Keywords: Major depression, Depressive symptoms, Depression remission

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Conflict of interest: Drs. Aikens, Klinkman, Kroenke, Nease and Sen have received research support from Eli Lilly, Inc. Dr. Aikens has served as paid consultant to Pfizer. Dr. Klinkman has served as a paid consultant to Wyeth Pharmaceuticals. Dr. Kroenke has received honoraria from Pfizer, Eli Lilly and Wyeth.

PII: S0163-8343(07)00193-4

doi:10.1016/j.genhosppsych.2007.10.003

General Hospital Psychiatry
Volume 30, Issue 1 , Pages 26-31, January 2008